The short answer
TB-500 carries no half-life extension technology, no fatty acid, no albumin binding, no protease-resistant substitutions beyond N-terminal acetylation. A 889 Da peptide is small enough to be filtered renally and is exposed to peptidases, so clearance is rapid.
Key facts
- Size
- 889.0 Da. Freely filtered by the kidney
- Half-life extension
- None
- Albumin binding
- No fatty acid conjugate
- N-terminal acetylation
- Blocks aminopeptidases only
- C-terminus
- Unprotected
- Endopeptidases
- Unaffected by terminal capping
Two clearance routes, both open
A molecule this small passes the glomerulus unimpeded, the filtration barrier retains things around 60 kDa and above, and 889 Da is far below any threshold. Separately, peptidases in plasma and tissue cleave peptide bonds. Neither route is obstructed by anything in TB-500's structure.
What acetylation does and does not do
Aminopeptidases remove residues from a free N-terminus. Capping that terminus with an acetyl group blocks them, which is a real protective effect. It does nothing about carboxypeptidases attacking the other end, and nothing at all about endopeptidases cleaving internally. One of three routes closed is useful but not transformative.
Research material referenced
TB-500 5mg, third-party HPLC tested
The contrast with engineered peptides
Semaglutide illustrates what deliberate half-life extension looks like: an Aib substitution blocking DPP-4, plus a C18 diacid binding albumin so the complex is too large to filter and is physically shielded. That combination takes GLP-1 from one to two minutes to about a week. TB-500 has none of it, which is a design difference rather than an oversight. The fragment was made to study a motif, not to be a durable agent.
Why this matters for interpreting studies
A compound cleared rapidly reaches its target briefly, and effects observed in a study depend on the exposure the protocol produced. Comparing outcomes between studies using different administration schedules is comparing different exposures, not different potencies. This is the sort of detail that separates a mechanistic result from a practical one.
The full protein is different again
Thymosin beta-4 at 4,963 Da is still well below the renal filtration threshold, so it is not protected by size either, but its pharmacokinetics are not the fragment's, and studies using the protein should not be read as characterising the peptide.
Frequently asked questions
Does TB-500 have a long half-life?
No. At 889 Da with no albumin binding or protease-resistant substitutions beyond N-terminal acetylation, clearance is rapid.
What does the acetyl group protect against?
Aminopeptidases attacking the N-terminus. It does not protect the C-terminus or block internal cleavage by endopeptidases.
Why not add albumin binding like semaglutide?
The fragment was made to study a motif rather than to function as a durable agent. Half-life extension is a deliberate engineering step that was never applied here.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubChemPubChem · TB-500 (CID 62707662)pubchem.ncbi.nlm.nih.gov
- PubMedHannappel E, beta-Thymosins: Ann N Y Acad Sci 2007 (PMID 17468232)pubmed.ncbi.nlm.nih.gov
- PubMedGoldstein AL et al., Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012 (PMID 22074294)pubmed.ncbi.nlm.nih.gov
- PubMedShrivastava S et al., Thymosin beta4 and cardiac repair. Ann N Y Acad Sci 2010 (PMID 20536454)pubmed.ncbi.nlm.nih.gov
- PubMedSosne G et al., Thymosin beta 4 promotes corneal wound healing. Exp Eye Res 2002 (PMID 11950239)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Thymosin β4 (RGN-259) dry eye Phase 3 (NCT03925727)clinicaltrials.gov
- PubChemPubChem · Thymosin β4 (CID 16132341)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More TB-500 (Thymosin β4 fragment) articles
- Cell Migration: What the Studies ReportMigration requires continual actin remodelling, which gives a sequestering protein a plausible route to affect it. What the assays measure and what they do not.
- Angiogenesis: What the Literature ReportsNew vessel formation requires endothelial cells to migrate, which connects it to actin biology. What the models show and why the mechanism is less direct here.
- TB-500 Benefits: What Is Established and What Is NotActin sequestration, migration, angiogenesis, corneal and cardiac repair models. Sorted by how well each is established and which compound was actually used.
- TB-500 in the Published ResearchHow to search a literature where the compound name and the studied molecule frequently differ, and what the search strategy should be.
- Fragment Research: The Logic and Its LimitsIsolating a motif attributes an effect to that motif. What that buys, what it costs, and why fragment results do not automatically transfer to the parent.